Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA approves Ironwood's Duzallo for gout

Jaime De Leon
August 28, 2017 11:09 PM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said FDA approved Duzallo lesinurad/allopurinol to treat hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with allopurinol alone.

The company expects to launch the fixed-dose combination early next quarter, and said it will elaborate on the specific price of the drug closer to launch. Ironwood said the pricing will be similar to that of Zurampic lesinurad, one of Duzallo’s components...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Astrazeneca plc

Grunenthal GmbH

Ironwood Pharmaceuticals Inc.